122 studies found for:    "Viral hemorrhagic fever"
Show Display Options
Rank Status Study
1 Enrolling by invitation Treatment of Viral Hemorrhagic Fevers With Intravenous Ribavirin in Military Treatment Facilities
Conditions: Crimean-Congo Hemorrhagic Fever;   Lassa Fever
Intervention: Drug: Ribavirin (Virazole) Injection
2 Enrolling by invitation Ribavirin for Hemorrhagic Fever With Renal Syndrome
Condition: Hemorrhagic Fever With Renal Syndrome
Intervention: Drug: Ribavirin
3 Enrolling by invitation Ribavirin for Hemorrhagic Fever With Renal Syndrome in Germany
Condition: Hemorrhagic Fever With Renal Syndrome
Intervention: Drug: Virazole (Ribavirin)
4 Recruiting Phase 2a Immunogenicity Study of Hantaan/Puumala Virus DNA Vaccine for Prevention of Hemorrhagic Fever
Condition: Hemorrhagic Fever With Renal Syndrome
Interventions: Biological: HTNV/PUUV DNA vaccine;   Biological: Placebo
5 Completed Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever
Conditions: Acquired Bleeding Disorder;   Dengue Haemorrhagic Fever
Interventions: Drug: activated recombinant human factor VII;   Drug: placebo
6 Completed Study to Evaluate the Safety, Tolerability, and Immunogenicity of Hantaan and Puumala Virus DNA Vaccines
Condition: Hemorrhagic Fever With Renal Syndrome
Intervention: Biological: Vaccine/device combination for prevention of HFRS
7 Completed Experimental Ebola Vaccine Trial
Conditions: Hemorrhagic Fever, Ebola;   Healthy
Intervention: Drug: VRC-EBODNA012-00-VP
8 Completed Experimental Vaccine for Prevention of Ebola Virus Infection
Conditions: Ebola Hemorrhagic Fever;   Ebola Virus Disease;   Ebola Virus Vaccines;   Envelope Glycoprotein, Ebola Virus;   Filovirus
Intervention: Drug: VRC-EBOADV018-00-VP
9 Completed Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers
Conditions: Dengue;   Dengue Hemorrhagic Fever;   Yellow Fever
Interventions: Biological: Live, attenuated dengue serotype 1, 2, 3, and 4 virus;   Biological: Yellow fever vaccine;   Biological: Measles, mumps, and rubella vaccine;   Biological: Pneumococcal Conjugated Vaccine;   Biological: Hepatitis A Pediatric Vaccine;   Biological: Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine;   Biological: Yellow Fever Vaccine;   Biological: Placebo (NaCl)
10 Completed Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects
Conditions: Dengue;   Dengue Fever;   Dengue Hemorrhagic Fever;   Dengue Virus
Intervention: Biological: Chimeric dengue serotype (1, 2, 3, 4)
11 Active, not recruiting Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore
Conditions: Dengue Fever;   Dengue Hemorrhagic Fever;   Dengue Virus;   Dengue Diseases
Interventions: Biological: CYD Dengue vaccine;   Biological: NaCl + influenza virus or hepatitis A vaccine
12 Completed Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US
Conditions: Dengue Fever;   Dengue Hemorrhagic Fever;   Dengue Virus
Intervention: Biological: ChimeriVax™ Tetravalent Dengue Vaccine
13 Completed Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years
Conditions: Dengue Virus;   Dengue Fever;   Dengue Hemorrhagic Fever;   Dengue Diseases
Interventions: Biological: Chimeric dengue serotype 1, 2, 3, and 4;   Biological: Pneumococcal polysaccharide vaccine
14 Completed Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India
Conditions: Dengue;   Dengue Fever;   Dengue Hemorrhagic Fever
Interventions: Biological: Live, attenuated, recombinant dengue serotype 1, 2, 3, 4 virus;   Biological: Placebo: NaCl 0.9% solution
15 Completed Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America
Conditions: Dengue;   Dengue Hemorrhagic Fever
Interventions: Biological: Live, attenuated, recombinant dengue serotype 1 , 2, 3 , and 4 virus;   Biological: NaCl 0.9%;   Biological: Tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccine adsorbed;   Biological: Meningococcal A+C vaccine
16 Completed Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children
Conditions: Dengue;   Dengue Fever;   Dengue Hemorrhagic Fever
Intervention:
17 Completed Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia
Conditions: Dengue Fever;   Dengue Hemorrhagic Fever
Interventions: Biological: Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus;   Biological: Placebo: NaCl 0.9%
18 Completed Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults
Conditions: Dengue Virus;   Dengue Fever;   Dengue Hemorrhagic Fever;   Dengue Diseases
Interventions: Biological: Bivalent CYD-1,3 Dengue (Vero) + Bivalent CYD-2,4 Dengue (Vero);   Biological: Tetravalent blending VDV-2/CYD-1,3,4 Dengue (Vero);   Biological: Tetravalent CYD-1,2,3,4 Dengue (Vero);   Biological: JE-VAX®: Japanese encephalitis virus vaccine inactivated + Tetravalent CYD-1,2,3,4 Dengue (Vero)
19 Active, not recruiting Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America
Conditions: Dengue Fever;   Dengue Hemorrhagic Fever;   Dengue
Interventions: Biological: Live, attenuated, dengue serotype 1, 2, 3, 4 virus;   Biological: Placebo: NaCl 0.9% solution
20 Active, not recruiting Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia
Conditions: Dengue;   Dengue Fever;   Dengue Hemorrhagic Fever
Interventions: Biological: Live, attenuated, dengue serotype 1, 2, 3, 4 virus;   Biological: Placebo: NaCl 0.9%

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years